We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Illumina

Illumina develops, manufactures and markets integrated systems for the analysis of genetic variations and biological ... read more Featured Products: More products

Download Mobile App




Targeted RNA-Sequencing Panel Detects Gene Fusions in Solid Tumors

By LabMedica International staff writers
Posted on 07 Dec 2021
Increasingly, rearrangements resulting in gene fusions have been revealed in multiple tumor types across diverse organ systems. More...
These gene fusions can drive tumorigenesis by altering gene expression and activity. Timely and reliable detection of fusions provides useful information to the pathologist and clinical team.

Molecular techniques, such as fluorescence in situ hybridization (FISH), reverse transcription PCR (RT-PCR), and Sanger and next-generation sequencing (NGS), have enabled discovery of characteristic fusions associated with particular tumors. With FISH and RT-PCR, the genes involved must be known or suspected, and usually only a few prioritized assays are run, due to cost and time limitations. These methods are not suitable for the identification of novel fusion partners.

Clinical Scientists at the Washington University School of Medicine (St. Louis, MO, USA) included 153 sarcoma and carcinoma cases submitted for FISH, RT-PCR, or DNA-based NGS testing during diagnostic workup between 2013 and 2019 that were identified retrospectively from their institutional database. Hematoxylin and eosin–stained slides and paraffin blocks were screened for adequate tissue (at least enough for a 1-mm punch, with ≥50% tumor cellularity in the punched area).

Deparaffinization and RNA extraction were performed using RecoverALL Total Nucleic Acid Isolation Kit for FFPE (Thermo Fisher Scientific, Waltham, MA). Quality of RNA and input amount were determined by Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA), with DV200 values, per TruSight RNA Fusion Panel kit protocol (Illumina, San Diego, CA, USA). Library preparation was performed using the TruSight RNA Fusion Panel kit. Sequencing was performed on the Illumina MiSeq and NextSeq 550 systems, using paired-end (2 × 75 nucleotides) reads.

The team reported that a total of 138 cases were successfully sequenced with adequate quality control metrics (90%). There were 110 sarcomas, with 31 sarcomas not otherwise specified, 25 Ewing sarcomas, and 13 synovial sarcomas, among others. A total of 101 of 138 (73%) cases were concordant by RNA sequencing and the prior test method. RNA sequencing identified an additional 30 cases (22%) with fusions that were not detected by conventional methods. In seven cases (5%), the additional fusion information provided by RNA sequencing would have altered diagnosis and management. A total of 19 (14%) novel fusion pairs, not previously described in the literature, were discovered.

The authors concluded that fusion analysis is a beneficial ancillary test that provides significant clinical value to the pathologist and treatment team. Targeted RNA sequencing on FFPE tissue is one method that enables the sensitive detection of multiple potential fusion genes simultaneously. This test could be performed at the time of pathologic examination in biopsy or resection specimens to aid in accurate diagnosis and clinical management. The study was published on December 1, 2021 in the Journal of Molecular Diagnostics.

Related Links:
Washington University School of Medicine
Thermo Fisher Scientific
Agilent Technologies
Illumina



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Gold Member
Connectivity Solution
EKF Link
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: New evidence now questions whether a single stool-test cutoff should be applied uniformly across all age groups.(Photo courtesy of Paul Maguire - Adobe Stock)

Study Questions Uniform Stool-Test Cutoff Across Age Groups

Colorectal cancer remains a major clinical challenge, ranking as the fourth most common cancer and the second-leading cause of cancer death in the U.K. Early-onset colorectal cancer, defined as diagnosis... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image

Labcorp Partners With Grupo Fleury to Expand Clinical Trial Operations in Brazil

Multinational clinical trials require laboratory partners that combine global expertise with local operational capabilities. Brazil is an important clinical research destination, supported by its diverse... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.